Involvement of KRAS G12A mutation in the IL-2-independent growth of a human T-LGL leukemia cell line, PLT-2

Nagoya Journal of Medical Science

Volumn 74, Issue 3-4, 2012, Pages 261-272

  Mizutani, Naoki ^a   Ito, Hiromi ^a   Hagiwara, Kazumi ^a   Kobayashi, Misa ^a   Hoshikawa, Asuka ^a   Nishida, Yayoi ^a   Takagi, Akira ^a   Kojima, Tetsuhito ^a   Suzuki, Motoshi ^a   Osawa, Yosuke ^b   Ohnishi, Kazunori ^c   Daibata, Masanori ^d   Murate, Takashi ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Graduate School of Medicine   (Japan)

^c Hamamatsu University School of Medicine   (Japan)

^d KOCHI UNIVERSITY   (Japan)

Author keywords

Human LGL leukemia cell lines; IL 2 independent growth; KRAS G12A mutation; MOTN 1 and PLT 2; Ras activity; Ras MAP ERK pathway

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE; FLAVONOID; INTERLEUKIN 15; INTERLEUKIN 2; KRAS PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN P21; RAS PROTEIN;

ARTICLE; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; HUMAN; LARGE GRANULAR LYMPHOCYTE LEUKEMIA; METABOLISM; MUTATION; TUMOR CELL LINE;

CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASES; CELL LINE, TUMOR; CELL PROLIFERATION; FLAVONOIDS; HUMANS; INTERLEUKIN-15; INTERLEUKIN-2; LEUKEMIA, LARGE GRANULAR LYMPHOCYTIC; MUTATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS P21(RAS); RAS PROTEINS;

EID: 84871859609     PISSN: 00277622     EISSN: 21863326     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Gilliland DG. Molecular genetics of human leukemias: new insights into therapy. Semin Hematol, 2002; 39: 6-11.
2. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell, 2006; 10: 515-527.
3. Solomon DA, Kim JS, Ressom HW, Sibenaller Z, Ryken T, Jean W. Sample type bias in the analysis of cancer genomes. Cancer Res, 2009; 69: 5630-5633.
4. Inaba T. Cytokine-mediated cell survival. Int J Hematol, 2004; 80: 210-214.
5. Schrader JW. Role of a single haemopoietic growth factor in multiple proliferative disorders of haemopoietic and related cells. Lancet, 1984; 2: 133-137.
6. Daibata M, Matsuo Y, Machida H, Taguchi T, Ohtsuki Y, Taguchi H. Differential gene-expression profiling in the leukemia cell lines derived from indolent and aggressive phases of CD56+ T-cell large granular lymphocyte leukemia. Int J Cancer, 2004; 108: 845-851.
7. Matsuo Y, Drexler HG, Takeuchi M, Tanaka M, Orita K. Establishment of the T-cell large granular lymphocyte leukemia cell line MOTN-1 carrying natural killer-cell antigens. Leuk Res, 2002; 26: 873-879.
8. Furuhata A, Kimura A, Shide K, Shimoda K, Murakami M, Ito H. p27 deregulation by Skp2 overexpression induced by the JAK2V617 mutation. Biochem Biophys Res Commun, 2009; 383: 411-416.
9. Zhang R, Shah MV, Yang J, Nyland SB, Liu X, Yun JK. Network model of survival signaling in large granular lymphocyte leukemia. Proc Natl Acad Sci USA, 2008; 105: 16308-16313.
10. Yang J, Liu X, Nyland SB, Zhang R, Ryland LK, Broeg K. Platelet-derived growth factor mediates survival of leukemic large granular lymphocytes via an autocrine regulatory pathway. Blood, 2010; 115: 51-60.
11. Chan G, Kalaitzidis D, Neel BG. The tyrosine phosphatase Shp2 (PTPN11) in cancer. Cancer Metastasis Rev, 2008; 27: 179-192.
12. Vamosi G, Bodnar A, Vereb G, Jenei A, Goldman CK, Langowski J. IL-2 and IL-15 receptor alpha-subunits are coexpressed in a supramolecular receptor cluster in lipid rafts of T cells. Proc Natl Acad Sci USA, 2004; 101: 11082-11087.
13. Epling-Burnette PK, Bai F, Wei S, Chaurasia P, Painter JS, Olashaw N. ERK couples chronic survival of NK cells to constitutively activated Ras in lymphoproliferative disease of granular lymphocytes (LDGL). Oncogene, 2004; 23: 9220-9229.
14. Ulku AS, Der CJ. Ras signaling, deregulation of gene expression and oncogenesis. Cancer Treat Res, 2003; 115: 189-208.
15. Zhang J, Wang J, Liu Y, Sidik H, Young KH, Lodish HF. Oncogenic Kras-induced leukemogeneis: hematopoietic stem cells as the initial target and lineage-specific progenitors as the potential targets for final leukemic transformation. Blood, 2009; 113: 1304-1314.
16. Guerrero S, Casanova I, Farre L, Mazo A, Capella G, Mangues R. K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Res, 2000; 60: 6750-6756.
17. Deschoolmeester V, Boeckx C, Baay M, Weyler J, Wuyts W, Van Marck E. KRAS mutation detection and prognostic potential in sporadic colorectal cancer using high-resolution melting analysis. Br J Cancer, 2010; 103: 1627-1636.
18. Seeburg PH, Colby WW, Capon DJ, Goeddel DV, Levinson AD. Biological properties of human c-Ha-ras1 genes mutated at codon 12. Nature, 1984; 312: 71-75.
19. Davidsson J, Paulsson K, Lindgren D, Lilljebjorn H, Chaplin T, Forestier E. Relapsed childhood high hyperdiploid acute lymphoblastic leukemia: presence of preleukemic ancestral clones and the secondary nature of microdeletions and RTK-RAS mutations. Leukemia, 2010; 24: 924-931.
20. Kiessling MK, Oberholzer PA, Mondal C, Karpova MB, Zipser MC, Lin WM. High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade. Blood, 2011; 117: 2433-2440.
21. Ricci C, Fermo E, Corti S, Molteni M, Faricciotti A, Cortelezzi A. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant. Clin Cancer Res, 2010; 16: 2246-2256.
22. Saadatpour A, Wang RS, Liao A, Liu X, Loughran TP, Albert I. Dynamical and structural analysis of a T cell survival network identifies novel candidate therapeutic targets for large granular lymphocyte leukemia. PLoS Comput Biol, 2011; 7: e1002267.
23. Choi YL, Moriuchi R, Osawa M, Iwama A, Makishima H, Wada T. Retroviral expression screening of oncogenes in natural killer cell leukemia. Leuk Res, 2005; 29: 943-949.
24. McGlynn AP, Padua RA, Burnett AK, Darley RL. Alternative effects of RAS and RAF oncogenes on the proliferation and apoptosis of factor-dependent FDC-P1 cells. Leuk Res, 2000; 24: 47-54.
25. Shinjyo T, Kurosawa H, Miyagi J, Ohama K, Masuda M, Nagasaki A. Ras-mediated up-regulation of survivin expression in cytokine-dependent murine pro-B lymphocytic cells. Tohoku J Exp Med, 2008; 216: 25-34.